n-3 fatty acids in patients with cardiac risk factors [4]

New England Journal of Medicine

Volumn 369, Issue 8, 2013, Pages 781-

  Čulić, Viktor ^a  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPOPROTEIN; OMEGA 3 FATTY ACID; PLACEBO;

CARDIOMETABOLIC RISK; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DIAGNOSTIC ERROR; DRUG EFFICACY; FATTY LIVER; HEART PROTECTION; HOSPITALIZATION; HUMAN; HYPERLIPOPROTEINEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LETTER; LIPOPROTEIN BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK REDUCTION; SEX DIFFERENCE; CARDIOVASCULAR DISEASE; FEMALE; MALE; NOTE;

CARDIOVASCULAR DISEASES; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; MALE;

EID: 84882792018     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1308780     Document Type: Letter

References (4)

1. Healy B. The Yentl syndrome. N Engl J Med 1991;325:274-6.
2. Merz CN. The Yentl syndrome is alive and well. Eur Heart J 2011;32:1313-5.
3. Maas AH, van der Schouw YT, Regitz-Zagrosek V, et al. Red alert for women's heart: the urgent need for more research and knowledge on cardiovascular disease in women: proceedings of the workshop held in Brussels on gender differences in cardiovascular disease, 29 September 2010. Eur Heart J 2011;32:1362-8.
4. Mozaffarian D, Wu JHY. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011;58:2047-67.